17 results about "Slow Release Formulation" patented technology

The present invention relates to a slow-release formulation. It relates also to the use of said repellent formulation, to a method of use thereof, and to a composition comprising said formulation. It further relates to PMD glucovanillin conjugate compound of formula (II), a process for preparing the compound of formula (II), and further to the use of the compound of formula (II) for the controlled release of PMD. It refers also to a process for isolating racemic cis / trans-PMD from an extract containing PMD.

The invention relates to a slow-release pesticide preparation containing modified montmorillonite and application of the slow-release pesticide preparation, and belongs to the technical field of pesticide preparations. Nano silicon dioxide and montmorillonite are mixed and calcined to form a rigid porous framework, then a complex generated by ferroferric oxide and chitosan is loaded on the surface of the composite framework through physical adsorption and interface bonding, and the slow-release pesticide preparation containing modified montmorillonite is obtained. The preparation method comprises the following steps: modifying montmorillonite to form modified montmorillonite, carrying out surface functionalization treatment with a silane coupling agent to enable the modified montmorillonite to cooperate with a polylactic acid-glycolic acid copolymer to form a compact shell layer, wrapping a pesticide inside, and carrying out selenylation treatment to form a composite structure of a rigid structure and the shell layer, so that the problem of weak mechanical strength of a traditional sustained release preparation is solved; the rigid framework can resist extrusion of field soil, the compact shell layer and the selenylation layer synergistically resist rain wash, and meanwhile, the layered barrier property of the montmorillonite and the antioxidant property of the selenylation layer form synergistic protection, so that the pesticide preparation still has a good retention rate under long-time ultraviolet irradiation, and the stability of the preparation in a complex field environment is remarkably improved.

The invention belongs to the field of biological feed, and discloses application of P.megatherium in preparation of an additive for inhibiting generation of greenhouse gas in animal waste. The P.megatherium is preserved in the Guangdong Microbial Culture Collection Center on April 18, 2025, and the preservation number is GDMCC NO: 66160. According to the present invention, the P.megatherium has efficient enzyme production capacity, and can efficiently decompose cellulose after the P.megatherium is planted in the rumen so as to significantly reduce the carbon emission of ruminants. Meanwhile, the probiotics with various enzyme production characteristics and propionibacterium are further compounded, so that the obtained intestinal probiotic composition has an obvious synergistic effect, and carbon emission is obviously reduced. Finally, a composition containing a fermentation product, an intestinal probiotic composition and a microcapsule with an insect grease slow-release function acts on the intestinal tract, and carbon emission of ruminants can be remarkably reduced.

The present invention provides an injectable depot composition comprising enavogliflozin and low-dose liraglutide. A combination regimen of enavogliflozin and low-dose liraglutide provides a synergistic effect in the treatment of obesity compared with the single administration of either drug. Furthermore, compared with the single administration of liraglutide, the administered dose of liraglutide can be reduced, and thereby the direct causes of gastrointestinal and cardiovascular side effects of liraglutide can be mitigated. Furthermore, the present invention has the additional advantage of providing an effect for alleviating metabolic diseases and cardiovascular diseases related to blood glucose, blood lipids, blood pressure, fatty liver, and the like through combined administration with enavogliflozin.Furthermore, the depot composition of enavogliflozin and liraglutide according to the present invention can significantly improve treatment convenience and treatment compliance for patients compared to existing liraglutide formulations, which are injected subcutaneously once daily, by unifying the route of administration and increasing the cycle of administration.

A delayed-release formulation for delivering an active pharmaceutical ingredient (API) to the colon, comprising a pellet having a core and a layered coating on the core, wherein the core comprises the API, and the layered coating comprises a first layer comprising a first film-forming polymer and a second layer comprising a second film-forming polymer, wherein the first film-forming polymer is a film-forming polymer that provides a pH-dependent release above pH 7.0, and the second film-forming polymer is a film-forming polymer that provides a pH-independent release.

The invention relates to the technical field of environmental response type pesticide preparations, and particularly discloses a sustained release preparation for preventing and treating meloidogyne meloidogyne diseases in saline-alkali soil and a preparation method of the sustained release preparation. The sustained release preparation for preventing and treating melon root knot nematode disease in saline-alkali soil is prepared from the following raw materials in percentage by mass: 55 to 57 percent of 30 percent fosthiazate microcapsule suspension, 19 to 21 percent of 15 percent fluopyram microcapsule suspension, 4 to 6 percent of response component, 5 to 7 percent of surfactant, 0.5 to 0.6 percent of thickening agent, 0.03 to 0.04 percent of preservative, 0.01 to 0.02 percent of defoaming agent and the balance of water, in addition, the preparation method disclosed by the invention has the advantages of realizing directional release and synergistic interaction of the fosthiazate and fluopyram compounded medicament and adapting to a high-pH environment of the saline-alkali soil.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The disclosure provides slow-release formulations of Glucagon-like peptide- 1 receptor agonist (GLP-1 RA), such as for example, semaglutide, tirzepatide, and survodutide, for treating obesity, type II diabetes and other metabolic disorders. The formulations are based on self- assembling peptides compositions, such as, for example, RADA16 and IEIK13.

Disclosed herein is an injectable depot formulation and use thereof for treating a mental disorder. The injectable depot formulation comprises cariprazine free base particles and a pharmaceutically acceptable carrier. The cariprazine free base particles have a median particle size by volume (Dv50) ranging from 0.5 μm to 100 μm.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The present invention relates to a slow release formulation. It relates also to the use of said repellent formulation, to a method of use thereof, and to a composition comprising said formulation. It further relates to PMD glucovanillin conjugate compound of formula (II), a process for preparing the compound of formula (II), and further to the use of the compound of formula (II) for the controlled release of PMD. It refers also to a process for isolating racemic cis / trans-PMD from an extract containing PMD.

It is an object of the present disclosure to provide a formulation for injectable and topical collagenase, which will have extended residence time for the drug at the therapeutic targeted area for the indication being treated. It is a further object of the disclosure to provide a slow release formulation for collagenase, which is compatible with the active ingredient and does not adversely affect its activity. Still a further object of the disclosure is to provide an injectable formulation for collagenase which can be effectively administered to a patient with a small size needle without exhibiting pre-gelation, which would interfere with the ability to deliver the required dose for treatment. Still a further object of the disclosure is to provide a water-based topical formulation for collagenase which will be more compatible with other topically used medications to achieve better results.

The invention provides compositions and methods for the treatment of depression and other psychiatric disorders. In particular, the invention provides sustained- or controlled-release formulations, particularly extended or slow release formulations, which include at least one monoamine oxidase inhibitor (MAOI), as well as combination therapies that include at least one MAOI and at least one norepinephrine-reuptake-inhibitor (NRI), for use in such compositions and methods. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.